Fortrea Holdings Inc.

What they do

Fortrea operates in one reporting segment, Clinical Services, and offers Full Service, Functional Service Provider (FSP), and Hybrid delivery models. The company has approximately 14,300 employees and conducts operations in approximately 100 countries across more than 20 therapeutic areas. It was spun off from Labcorp Holdings Inc. on June 30, 2023, and trades on Nasdaq under FTRE.

Revenue drivers

• Clinical Development — Fortrea's largest offering by annual revenue contribution, providing phase I through IV clinical and real-world evidence studies with flexible delivery models.
• Clinical Pharmacology — Integrated early-stage solution including clinical research units (CRUs) in Leeds, Dallas, Daytona, and Madison, offering first-in-human and exploratory studies, bioanalytics, pharmacokinetics, and modeling.
• Consulting services — Advisory services provided alongside clinical trial management and clinical pharmacology to biopharmaceutical, biotechnology, and medical device customers.

Recent performance

For the second quarter of 2026, Fortrea reported revenues of $678.2 million, compared with $710.3 million in the second quarter of 2025. GAAP net loss was $(13.2) million, or $(0.14) per diluted share, versus a $(374.9) million net loss in the prior-year quarter that included a $309.1 million non-cash goodwill impairment charge. Adjusted EBITDA was $58.7 million, up from $54.9 million a year earlier, and adjusted diluted EPS was $0.23. Book-to-bill for the quarter was 1.06x, the fourth consecutive quarter above 1.0x, and backlog as of June 30, 2026 was $7,800 million.

Strategy

Management emphasizes commercial execution, operational excellence, and financial discipline as it pursues sustainable growth and margin expansion. The company reported four consecutive quarters with a book-to-bill ratio above 1.0x, contributing to a 1.12x book-to-bill for the trailing 12 months. CEO Anshul Thakral stated the company remains focused on building trusted client partnerships and advancing therapies. No specific new investment programs or capital allocation changes were detailed in the provided excerpts beyond the guidance increase.

Risks

• New business awards — The company may be materially adversely affected if it fails to generate a large number of net new business awards, or if awards are delayed, terminated, reduced in scope, or fail to go to contract.
• Customer and therapeutic concentration — Concentration in certain customers or therapeutic areas could have a material adverse effect on Fortrea's business, financial condition, results of operations, or cash flows.
• Backlog realization — Fortrea's backlog might not be indicative of future revenues, and the company might not realize all anticipated future revenue reflected in its backlog.
• Key personnel and staffing — An inability to attract and retain experienced and qualified personnel, including key management personnel, or increased personnel costs could adversely affect the business.

Outlook

Fortrea increased its full-year 2026 guidance to revenues of $2,620 million to $2,690 million and adjusted EBITDA of $205 million to $220 million. The company pointed to four consecutive quarters of book-to-bill above 1.0x as evidence of commercial progress. Management expressed confidence in the business and remains focused on its strategic journey toward sustainable growth and margin expansion.